Ergün Deniz, Kaçar Pelin, Özbakır Hıncal, Gülderen Mustafa, Çelebi Miray Yılmaz, Gürbüz Ege, Özenen Gizem Güner, Özer Arife, Kara Aybüke Akaslan, Ayhan Fahri Yüce, Ecevit Çigdem Ömür, Bekem Özlem, Bayram Süleyman Nuri, Devrim İlker
Department of Pediatric Infectious Diseases, University of Health Sciences Dr. Behçet Uz Childrens Hospital, İzmir, Turkey.
Department of Pediatrics, University of Health Sciences Dr. Behçet Uz Children's Hospital, İzmir, Turkey.
Eur J Pediatr. 2024 Dec 16;184(1):85. doi: 10.1007/s00431-024-05918-4.
Infectious gastroenteritis is an important cause of morbidity and mortality, especially in nations with middle and low incomes. In a pediatric gastroenteritis patient, the aim was to determine the therapeutic impact of using the Gastrointestinal Panel in our clinical practice. A single-center retrospective study was designed to evaluate children who were admitted to the hospital for gastroenteritis and had a gastrointestinal panel between August 2021 and January 2024. 103 patients who had gastrointestinal (GI) panel results were included in the study. The GI Panel positivity rate among 103 patients was 55.3% (n = 57). Bacterial agents were positive in 25 patients (43.8%), viral agents were found in 11 patients (19.2%), and polymicrobial agents were found positive in 21 patients (36.8%). Escherichia coli (9.1%) was the most common bacterial pathogen, and viral pathogens most frequently included Rotavirus (11.6%) and Norovirus (11.6%). When the effect of the GI Panel test on treatment was determined, the treatment of 51 (49.5%) patients was changed according to GI Panel.
In our study, the treatment regimen of many patients was adjusted based on the GI panel results in patients presenting with gastroenteritis. GI panel had an important impact on the patients care and optimization according to the principles of antimicrobial treatment. GI panel tests had several advantages such as speed and diagnostic accuracy as good as stool culture.
• Infectious gastroenteritis is a major cause of morbidity and mortality, especially in middle- and low-income countries. • BioFire® FilmArray, Gastrointestinal Panel (BioFire- Biomerieux, France) is a rapid and simple technique that uses nested multiplex PCR to detect gastrointestinal pathogens rapidly.
• In this study, the GI Panel test was found to have a cumulative impact on 49.5% (n=51) of the clinician's treatment modalities. • With its speed and diagnostic sensitivity, the GI Panel may provide clinicians with an important tool in the fight against antibiotic resistance by decreasing antimicrobial drug treatment at the children with gastroenteritis.
感染性肠胃炎是发病和死亡的重要原因，尤其是在中低收入国家。对于儿科肠胃炎患者，本研究旨在确定在我们的临床实践中使用胃肠道检测板的治疗效果。设计了一项单中心回顾性研究，以评估2021年8月至2024年1月期间因肠胃炎入院且进行了胃肠道检测板检测的儿童。103例有胃肠道（GI）检测板结果的患者被纳入研究。103例患者中GI检测板阳性率为55.3%（n = 57）。细菌病原体在25例患者中呈阳性（43.8%），病毒病原体在11例患者中被发现（19.2%），混合病原体在21例患者中呈阳性（36.8%）。大肠杆菌（9.1%）是最常见的细菌病原体，病毒病原体最常见的包括轮状病毒（11.6%）和诺如病毒（11.6%）。当确定GI检测板检测对治疗的影响时，51例（49.5%）患者的治疗根据GI检测板结果进行了改变。
在我们的研究中，许多肠胃炎患者的治疗方案根据GI检测板结果进行了调整。GI检测板对抗菌治疗原则下的患者护理和优化产生了重要影响。GI检测板检测具有速度快和诊断准确性与粪便培养相当等多个优点。
• 感染性肠胃炎是发病和死亡的主要原因，尤其是在中低收入国家。• BioFire® FilmArray胃肠道检测板（法国BioFire-生物梅里埃公司）是一种快速简单的技术，使用巢式多重PCR快速检测胃肠道病原体。
• 在本研究中，发现GI检测板检测对临床医生49.5%（n = 51） 的治疗方式产生了累积影响。• 凭借其速度和诊断敏感性，GI检测板可为临床医生提供一种重要工具，通过减少肠胃炎儿童的抗菌药物治疗来对抗抗生素耐药性。
